New data backs up Novartis’ Afinitor in treating rare tumour disorder
This article was originally published in Scrip
Executive Summary
New data examining three already marketed drugs are giving new hope to patients with a rare genetic tumour-growth disorder that those medicines may effectively treat their disease, known as tuberous sclerosis complex (TSC), which affects about 1 million people worldwide, 50,000 of which are in the US.